Aligos Therapeutics, Inc.
aligos.comWhat Do They Do?
Develops drug candidates for liver diseases, metabolic conditions and viral infections.
10-K for FY2025, filed Mar 5, 2026
How Do They Make Money?
Partners pay upfront for research and licensing rights, with additional development, regulatory and sales milestones possible; the company earns research payments as work progresses, while royalties are tied to partner product sales.
10-K for FY2025, filed Mar 5, 2026The Company enters into revenue arrangements with certain partners. Consideration under these contracts may include an upfront payment…View ↗
The Company may also perform research and development activities under the revenue agreements where the Company may be granted licenses…View ↗
In May 2023, the Company and Amoytop Biotech Co., Ltd (Amoytop) entered into a Research Collaboration and Development Agreement (the…View ↗
The Company determined that the Amoytop agreement falls within the scope of ASC 606. The agreement did not fall under the ASC 808 guidance…View ↗
$2.2M
-
10-K for FY2025, filed Mar 5, 2026
$2.2M ↗
Who Are Their Customers?
The company works with pharmaceutical partners, including Amoytop, through research and licensing agreements; its assets are pre-commercial, and it has no established sales or distribution capabilities.
10-K for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $24.2M in FY2025.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$1.5MView ↗
- ▼ −91% (Loss)
- vs −$15.9M in Q2 FY2025
-
Apr 21, 2026
Grants Amoytop regional rights to develop and sell pevifoscorvir sodium
Amoytop is to pay an upfront amount and may owe milestones and sales royalties, while taking responsibility for development and commercialization in the licensed territories.
Sources
8-K, filed Apr 21, 2026
On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop…View ↗
Focus shifts toward hepatitis B
The older report emphasized NASH and coronavirus programs; the latest makes chronic HBV the primary focus while continuing work on MASH, obesity and coronavirus infections.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 5, 2026
Who Do They Compete With?
Competes with Roche, Gilead Sciences, Bristol-Myers Squibb, Arbutus Biopharma, Ionis Pharmaceuticals, GlaxoSmithKline, Arrowhead Pharmaceuticals, Janssen Pharmaceuticals, Precision BioSciences, Assembly Biosciences, Dynavax Technologies, Johnson & Johnson, Merck, Replicor, Madrigal Pharmaceuticals, Novo Nordisk, AbbVie, AstraZeneca, Eli Lilly, and Pfizer
10-K for FY2025, filed Mar 5, 2026Current FDA-approved treatments for chronic HBV infection include peg-IFNα, marketed by Roche Holding AG (Roche), and oral antiviral agents…View ↗
Loading...
